Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dilan Athauda

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|February 15, 2020
Diabetes, BMI, and Parkinson'sTom Foltynie, Dilan Athauda
Parkinsonism & Related Disorders|August 9, 2016
Challenges in detecting disease modification in Parkinson's disease clinical trialsDilan Athauda, Thomas Foltynie
CNS Drugs|August 2, 2018
Drug Repurposing in Parkinson's DiseaseDilan Athauda, Thomas Foltynie
Nature Reviews. Neurology|December 3, 2014
The ongoing pursuit of neuroprotective therapies in Parkinson diseaseDilan Athauda, Thomas Foltynie
Progress in Brain Research|April 6, 2020
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experienceTom Foltynie, Dilan Athauda
Movement Disorders Clinical Practice|February 26, 2019
Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies TreatmentTom Foltynie, Dilan Athauda
BMJ (Clinical Research Ed.)|January 11, 2012
A restless night's sleepDilan Athauda, Guy Leschziner
Drug Discovery Today|February 7, 2016
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionDilan Athauda, Thomas Foltynie
Neuropharmacology|September 21, 2017
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's diseaseDilan Athauda, Thomas Foltynie
The New England Journal of Medicine|October 2, 2014
Images in clinical medicine. Evolving infarction in the anterior circulationDilan Athauda, Garryck Shernshih Tan
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Movement Disorders : Official Journal of the Movement Disorder Society|February 15, 2020
Diabetes, BMI, and Parkinson'sTom Foltynie, Dilan Athauda
Parkinsonism & Related Disorders|August 9, 2016
Challenges in detecting disease modification in Parkinson's disease clinical trialsDilan Athauda, Thomas Foltynie
CNS Drugs|August 2, 2018
Drug Repurposing in Parkinson's DiseaseDilan Athauda, Thomas Foltynie
Nature Reviews. Neurology|December 3, 2014
The ongoing pursuit of neuroprotective therapies in Parkinson diseaseDilan Athauda, Thomas Foltynie
Progress in Brain Research|April 6, 2020
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experienceTom Foltynie, Dilan Athauda
Movement Disorders Clinical Practice|February 26, 2019
Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies TreatmentTom Foltynie, Dilan Athauda
BMJ (Clinical Research Ed.)|January 11, 2012
A restless night's sleepDilan Athauda, Guy Leschziner
Drug Discovery Today|February 7, 2016
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionDilan Athauda, Thomas Foltynie
Neuropharmacology|September 21, 2017
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's diseaseDilan Athauda, Thomas Foltynie
The New England Journal of Medicine|October 2, 2014
Images in clinical medicine. Evolving infarction in the anterior circulationDilan Athauda, Garryck Shernshih Tan
Pageof 6